Sealing Shielding

What to Know About O-ring Cytotoxicity and the Pharmaceutical Industry

what to know about o-ring cytotoxicity and the pharmaceutical industry, o-ring, oring, o ring, medical device sealsMost pharmaceutical manufacturers produce drugs in large vats of living cell cultures. For the production of these drugs, it is extremely important to ensure that these cell cultures are not exposed to any cytotoxic contaminants that may leach out of the seals. It is also imperative that cytotoxic contaminants not be present in the finished drug, especially for infants, and for patients who are pregnant or nursing.

Cytotoxicity O-ring testing

Before an O-ring is approved for the pharmaceutical industry, it needs to be tested for cytotoxicity (cell toxicity). This is usually tested in the United States per USP <87>, and internationally per ISO 10993-5. These two tests are very similar in methodology and criteria. Both cytotoxicity tests use L-929 mouse fibroblast cells, which are an industry-standard cell used for cytotoxicity testing. Cultures of these cells are produced in glass flasks prior to testing. Extracts are prepared using 3 test articles: the O-ring material, a negative control article (HDPE), and a positive control article (PVC for USP <87>, and powder-free latex gloves for ISO 10993-5). These extracts are then added to the cell cultures. Cells are incubated with the extracts and then examined after 48 hours. The grading scale is from 0 to 4, with 0 meaning cells are completely unaffected, and 4 meaning all cells are destroyed. For the test to be valid, the HDPE extract must have a grade of 0, and the PVC extract must have a grade of 3 or 4. The O-ring material meets the requirements if the biological response is less than or equal to grade 2. Materials that pass the requirements of USP <87> or ISO 10993-5 are generally considered non-toxic to cells.

Parker offers several O-ring compounds that have been tested for cytotoxicity. 

USP <87> Approved ISO 10993-5 Approval
Ethylene Propylene (EPDM) Ethylene Propylene (EPDM)
E1244-70 E1244-70
E3609-70 E3609-70
E0740-75  
Silicone (VMQ)  
S1138-70  
SM355-75  
Perfluoroelastomer (FFKM)  
FF580-75  
  Fluorocarbon (FKM)
  V1274-80

If you have any questions or would like to learn more about O-ring Cytotoxicity testing, please feel free to contact Parker applications engineering or check out our interactive O-Ring eHandbook.

 

David Mahlbacher, applications engineer

 

 

This article was contributed by David Mahlbacher, applications engineer, Parker O-Ring Division

 

 

 

 

Perfluoroelastomer Materials Tailored for Your Needs

A Simple Guide to Selecting an O-Ring

Environmental Seal Enclosure 101

Categories
Recent Posts by Author

New High Performance Compound for Automotive Applications

Parker Chomerics THERM-A-GAP TC50 is the latest in the family of soft thermal conductive silicone elastomers developed to conduct heat between a hot component and a heatsink or enclosure. The...

Rapid Prototype Program Reduces Seal Project Lead Time

The O-Ring & Engineered Seals Division is now offering a rapid prototype program for solid and hollow spliced O-rings that will reduce lead times on small orders to improve sample and trial testing on...

Continuous Molding Enables Production of Large-Size Elastomer Seals in Precision Quality

Precision O-rings are manufactured by vulcanization in a closed mold using compression or injection molding. This makes it possible to produce O-rings in relatively small manufacturing tolerances...
Comments

Comments for What to Know About O-ring Cytotoxicity and the Pharmaceutical Industry


Please note that, in an effort to combat spam, comments with hyperlinks will not be published.

Leave a comment





Captcha